|
|
| Acenocoumarol 4mg |
|
|
Actual product may differ in appearance from image shown |
 |
 |
|
| |
1 blister = 10 pills| 3 blister = 66 $( 2.2 $ per pill ) | Buy | | 6 blister = 126 $( 2.1 $ per pill ) | Buy | | 9 blister = 180 $( 2 $ per pill ) | Buy | | 12 blister = 228 $( 1.9 $ per pill ) | Buy |
|
|
| Made in: India |
Brand Name:Sintrom 4 mg
Generic Name:Acenocoumarol
Acenocoumarol decrease the clotting ability of the blood and therefore help to prevent harmful clots from forming
in the blood vessels.
Acenocoumarol is sometimes called blood thinner, although they do not actually thin the blood.
They also will not dissolve clots that already have formed, but they may prevent the clots from becoming
larger and causing more serious problems. Acenocoumarol is often used as treatment for certain blood vessel, heart, and lung conditions. |
Therapeutic actions:
Coumarin derivatives are vitamin K antagonists. They inhibit the carboxylation of certain glutamic acid molecules which are located at several sites near the terminal end both of coagulation factors II (prothrombin), VII, IX, and X, and of protein C or its cofactor protein S. This ?-carboxylation has a significant bearing on interaction of the aforementioned coagulation factors with Ca ions. Without this reaction, blood clotting cannot be initiated. Precisely how coumarin derivatives prevent vitamin K from bringing about ?-carboxylation of the glutamic acid molecules in these coagulation factors has not yet been determined. Depending on the size of the initial dosage, acenocoumarol causes prolongation of the thromboplastin time within approx. 36 - 72 hours. Following withdrawal of the medication the thromboplastin time usually reverts to normal after a few days
Contraindications and cautions:
• Known hypersensitivity to acenocoumarol and related Acenocoumarol derivatives or to excipients.
• Pregnancy.
• In patients unable to cooperate and who are unsupervised (e.g. unsupervised senile patients, alcoholics and patients with psychiatric disorders).
Sintrom 4 mg is also contraindicated in conditions where the risk of haemorrhage is greater than the possible clinical benefit, e.g.:
• Haemorrhagic diathesis or haemorrhagic blood dyscrasia.
• Shortly before or aftersurgical intervention on the central nervous system, as well as eye operations and traumatising surgery involving extensive exposure of tissues.
• Peptic ulcers or haemorrhage in the gastrointestinal tract, urogenital tract, or respiratory system, as well as cerebrovascular haemorrhages, acute pericarditis and pericardial effusion, and infective endocarditis.
• Severe hypertension, severe hepatic or renal disease.
• Increased fibrinolytic activity as encountered after operations on the lung, prostate, uterus, etc
Side effects:
More common side effects may include:
Hemorrhage: Signs of severe bleeding resulting in the loss of large amounts of blood depend upon the location and extent of bleeding.
Symptoms include: chest, abdomen, joint, muscle, or other pain; difficult breathing or swallowing; dizziness; headache; low blood pressure; numbness and tingling; paralysis; shortness of breath; unexplained shock; unexplained swelling; weakness Less common side effects may include: Abdominal pain and cramping, diarrhea, allergic reactions, fatigue, hepatitis,feeling cold and chills, loss of hair, feeling of illness, fever, fluid retention and swelling, gas and bloating, hives, intolerance to cold, itching, lethargy, liver damage, yellowed skin and eyes, loss of hair, nausea, necrosis (gangrene), pain, purple toes, rash, severe or long-lasting inflammation of the skin, taste changes, vomiting, yellowed skin and eyes.
Interactions:
Acenocoumarol may potentiate the anticoagulant effect of Sintrom 4 mg: Allopurinol, anabolic steroids, androgens, antiarrhythmic agents (e.g. amiodarone, quinidine), antibiotics (e.g. erythromycin, tetracyclines, neomycin, chloramphenicol and amoxycillin), clofibric acid as well as derivatives and structural analogues of clofibric acid, disulfiram, ethacrynic acid, glucagon, cimetidine, imidazole derivatives (e.g. metronidazole and, even when administered locally, miconazole), sulfonamides including co-trimoxazole (=sulfamethoxazole + trimethoprim), sulphonylureas such as tolbutamide and chlorpropamide, thyroid hormones (incl. dextrothyroxine), sulfinpyrazone, simvastatin, and tamoxifen.
Acenocoumarol alter haemostasis and may potentiate the anticoagulant activity of Sintrom 4 mg and thereby increasing the risk of gastrointestinal haemorrhage: Heparin, platelet-aggregation inhibitors such as salicylic acid and its derivatives (e.g. acetylsalicylic acid, para-aminosalicylic acid, diflunisal), phenylbutazone or other pyrazolone derivatives (sulfinpyrazone), and other non-steroidal anti-inflammatory drugs. Use of Sintrom 4 mg together with these substances is therefore highly unadvisable. When Sintrom 4 mg is prescribed in combination with these drugs, coagulation tests should be performed more frequently.
Acenocoumarols may diminish the anticoagulant effect of Sintrom 4 mg:
Aminoglutethimide, barbiturates, carbamazepine, cholestyramine (see under iOverdosei), griseofulvin, oral contraceptives, and rifampicin.
Other interactions
During concomitant treatment with Acenocoumarol, the serum hydantoin concentration may rise.
Sintrom 4 mg may potentiate the hypoglycaemic effect of sulfonylurea derivatives. Since neither
the severity nor the early signs of interactions can be predicted, patients taking Sintrom 4 mg,
especially if they also suffer from hepatic dysfunction, should limit their alcohol intake
|
|
|
|
|
|
 |
 |
|
|